NHI.no
Annonse
Informasjon

Nedsatt blodsirkulasjon i beina

Claudicatio intermittens, "røykeben", er smerter i beina på grunn av for dårlig blodsirkulasjon i pulsårene (arteriene).

Åreforkalkning, det vil si avleiring av kolesterol og fettpartikler på innsiden av blodårene, er årsaken til "røykeben"

Sist oppdatert:

23. nov. 2021

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Perifer arteriell sykdom . Referanselisten for dette dokumentet vises nedenfor

  1. Aboyans V, Ricco JB, Bartelink MEL, et al; ESC Scientific Document Group. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO), the Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 2018; 39: 763-816. PMID:28886620. PubMed
  2. Tran B. Assessment and management of peripheral arterial disease: what every cardiologist should know. Heart 2021. pmid:33985986 PubMed
  3. Allison MA, Ho E, Denenberg JO, et al. Ethnic-specific prevalence of peripheral arterial disease in the United States. 2007 American Journal of Preventive Medicine 2007;32:328-333
  4. Sigvant B, Wiberg-Hedman K, Bergqvist D, et al. A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences. J Vasc Surg. 2007;45:1185-1191 PubMed
  5. Koutakis P, Johanning JM, Haynatzki GR, et al. Abnormal joint powers before and after the onset of claudication symptoms. J Vasc Surg 2010; 52: 340-7. PubMed
  6. Joosten MM, Pai JK, Bertoia ML, et al. Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men. JAMA 2012; 308: 1660-7. Journal of the American Medical Association
  7. Thomas PE, Vedel-Krogh S, Nielsen SF, Nordestgaard BG, Kamstrup PR. Lipoprotein(a) and Risks of Peripheral Artery Disease, Abdominal Aortic Aneurysm, and Major Adverse Limb Events. J Am Coll Cardiol 2023; 82: 2265-2276. pmid:38057068 PubMed
  8. Anderson JL, Halperin JL, Albert NM, et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.. Circulation 2013; 127: 1425-43. pmid:23457117 PubMed
  9. Khan NA, Rahim SA, Anand SS, Simel DL, Panju A. Does the clinical examination predict lower extremity peripheral arterial disease?. JAMA 2006; 295: 536-46. PubMed
  10. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45 Suppl S:S5. PMID: 17223489 PubMed
  11. Herraiz-Adillo A, Cavero-Redondo I, Alvarez-Bueno C, et al. The accuracy of an oscillometric ankle-brachial index in the diagnosis of lower limb peripheral arterial disease: A systematic review and meta-analysis. Int J Clin Pract. 2017. PMID: 28851093 PubMed
  12. Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2017; 135: 726-79. pmid:27851992 PubMed
  13. Layden J, Michaels J, Bermingham S, Higgins B. Diagnosis and management of lower limb perpheral arterial disease: summary of NICE guidance. BMJ 2012; 345: e4947. BMJ (DOI)
  14. Menke J, Larsen J. Meta-analysis: Accuracy of contrast-enhanced magnetic resonance angiography for assessing steno-. Ann Intern Med 2010; 153: 325-34. Annals of Internal Medicine
  15. de Vries M, Ouwendijk R, Flobbe K, et al. Peripheral arterial disease: clinical and cost comparisons between duplex US and contrast-enhanced MR angiography--a multicenter randomized trial. Radiology 2006; 240: 401-10. Radiology
  16. Met R, Bipat S, Legemate DA, Reckers JA, Koelemay MJW. Diagnostic performance of computed tomography angiography in peripheral arterial disease. A systematic review and meta-analysis. JAMA 2009; 301: 415-24. Journal of the American Medical Association
  17. Shirasu T, Takagi H, Yasuhara J, et al. Long-term outcomes of exercise therapy versus revascularization in patients with intermittent claudication. Ann Surg 2023; 278: 172-178. PMID: 36728522 PubMed
  18. National Institute for Health and Clinical Excellence. Lower limb peripheral arterial disease: diagnosis and management. (Clinical guideline 147) 2012
  19. Lane R, Ellis B, Watson L, et al. Exercise for intermittent claudication. Cochrane Database Syst Rev. 2014 ;7:CD000990. DOI: 10.1002/14651858.CD000990.pub3. DOI
  20. Parmenter BJ, Dieberg G, Smart NA. Exercise training for management of peripheral arterial disease: a systematic review and meta-analysis. Sports Med. 2015 Feb;45(2):231-44. doi: 10.1007/s40279-014-0261-z DOI
  21. McDermott MM, Spring B, Tian L, et al. Effect of Low-Intensity vs High-Intensity Home-Based Walking Exercise on Walk Distance in Patients With Peripheral Artery Disease The LITE Randomized Clinical Trial. JAMA 2021; 325: 1266-76. pmid:33821898 PubMed
  22. Lane R, Ellis B, Watson L, Leng GC. Exercise for intermittent claudication. Cochrane Database of Systematic Reviews 2014, Issue 7. Art. No.: CD000990. DOI: 10.1002/14651858.CD000990.pub3. DOI
  23. Hageman D, Fokkenrood HJP, Gommans LNM, van den Houten MML, Teijink JAW. Supervised exercise therapy versus home‐based exercise therapy versus walking advice for intermittent claudication. Cochrane Database of Systematic Reviews 2018, Issue 4. Art. No.: CD005263. DOI: 10.1002/14651858.CD005263.pub4. DOI
  24. Mazari FA, Khan JA, Carradice D, et al. Randomized clinical trial of percutaneous transluminal angioplasty, supervised exercise and combined treatment for intermuittent claudication due to femoropopliteal arterial disease. Br J Surg 2012; 99: 39-48. PubMed
  25. Saxton JM, Zwierska I, Blagojevic M, et al. Upper- versus lower-limb aerobic exercise training on health-related quality of life in patients with symptomatic peripheral arterial disease. J Vasc Surg 2011; 53: 1265-73. PubMed
  26. Van Schaardenburgh M, Wohlwend M, Rognmo Ø, Mattsson E. Calf raise exercise increases walking performance in patients with intermittent claudication. J Vasc Surg 2017; 65: 1473-82. pmid:28285932 PubMed
  27. Stead LF, Buitrago D, Preciado N, Sanchez G, Hartmann-Boyce J, Lancaster T. Physician advice for smoking cessation. Cochrane Database of Systematic Reviews 2013, Issue 5. Art. No.: CD000165. DOI: 10.1002/14651858.CD000165.pub4. DOI
  28. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease. A meta-analysis of randomized trials. JAMA 2009; 301: 1909-19. Journal of the American Medical Association
  29. Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA 2006; 295: 547-53. PubMed
  30. Helsedirektoratet. Nasjonal faglig retningslinje for forebygging av hjerte- og karsykdom. Helsedirektoratet. Sist faglig oppdatert: 05. mars 2018. www.helsedirektoratet.no
  31. Wong PF, Chong LY, Mikhailidis DP, Robless P, Stansby G. Antiplatelet agents for intermittent claudication. Cochrane Database of Systematic Reviews 2011, Issue 11. Art. No.: CD001272. DOI: 10.1002/14651858.CD001272.pub2. DOI
  32. Fowkes FG, Price JF, Stewart MC, et al. Aspirin for prevention of cardiovascular events in a generela population screende for a low ankle brachial index: a randomized controlled trial. JAMA 2010; 303: 841-8. Journal of the American Medical Association
  33. Paraskevas KI, Wierzbicki AS, Mikhailidis DP. Statins and noncardiac vascular disease. Curr Opin Cardiol. 2012;27(4):392–397.
  34. Bonaca MP, Nault P, Giugliano RP, et al. Low-Density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the Fourier trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation 2018;137:338–50. PMID: 29133605 PubMed
  35. Paravastu SC, Mendonca DA, Da Silva A. Beta blockers for peripheral arterial disease. Cochrane Database Syst Rev. 2013 Sep 11;9:CD005508. Cochrane (DOI)
  36. de Backer TLM, Vander Stichele R, Lehert P, Van Bortel L. Naftidrofuryl for intermittent claudication. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD001368. DOI: 10.1002/14651858.CD001368.pub4. DOI
  37. Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018;391:219–29. PMID: 29132880 PubMed
  38. Eikelboom JW, Bhatt DL, Fox KAA, et al. Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. J Am Coll Cardiol. 2021 Jul 6;78(1):14-23. PMID: 34210409 PubMed
  39. Hess CN, Debus ES, Nehler MR, et al. Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD. Circulation 2021; 144: 1831-41. pmid:34637332 PubMed
  40. Cosmi B, Conti E, Coccheri S. Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication. Cochrane Database of Systematic Reviews 2014, Issue 5. Art. No.: CD001999. DOI: 10.1002/14651858.CD001999.pub2. DOI
  41. Stevens JW, Simpson E, Harnan S, et al. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg 2012; 99: 1630-8. pmid:23034699 PubMed
  42. Bedenis R, Stewart M, Cleanthis M, et al. Cilostazol for intermittent claudication. Cochrane Database Syst Rev 2014; 10: CD003748. doi:10.1002/14651858.CD003748.pub4. DOI
  43. Salhiyyah K, Forster R, Senanayake E, et al. Pentoxifylline for intermittent claudication. Cochrane Database Syst Rev 2015; 9: CD005262. doi:10.1002/14651858.CD005262.pub3 DOI
  44. Gorenoi V, Brehm MU, Koch A, Hagen A. Growth factors for angiogenesis in peripheral arterial disease. Cochrane Database of Systematic Reviews 2017, Issue 6. Art. No.: CD011741. DOI: 10.1002/14651858.CD011741.pub2 DOI
  45. McDermott MM, Bazzano L, Peterson CA, et al. Effect of Telmisartan on Walking Performance in Patients With Lower Extremity Peripheral Artery Disease The TELEX Randomized Clinical Trial. JAMA 2022; 328: 1315-25. pmid:36194220 PubMed
  46. Fakhry F, Fokkenrood HJP, Spronk S, Teijink JAW, Rouwet EV, Hunink MGM. Endovascular revascularisation versus conservative management for intermittent claudication. Cochrane Database of Systematic Reviews 2018, Issue 3. Art. No.: CD010512. DOI: 10.1002/14651858.CD010512.pub2 DOI
  47. Pedersen G, Laxdal E, Jonung T, Aune S. Claudicatio intermittens - diagnostikk og behandling. Tidsskr Nor Lægeforen 2007; 127: 167-70. PubMed
  48. Malgor RD, Alalahdab F, Elraiyah TA, et al. A systematic review of treatment of intermittent claudication in the lower extremities. Vasc Surg. 2015;61:54S-73S. doi: 10.1016/j.jvs.2014.12.007 DOI
  49. Antoniou GA, Georgiadis GS, Antoniou SA, Makar RR, Smout JD, Torella F. Bypass surgery for chronic lower limb ischaemia. Cochrane Database of Systematic Reviews 2017, Issue 4. Art. No.: CD002000. DOI: 10.1002/14651858.CD002000.pub3. DOI
  50. Bradbury AW, Adam DJ, Bell J, et al. Bypass versus angioplasty in severe ischaemia if the leg (BASIL) trial: an intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy. J Vasc Surg 2010; 51: 5-17. PubMed
  51. Flørenes T, Sandbæk G, Stranden E, Jørgensen JJ. Kirurgisk behandling av aterosklerose i undersktremitetene. Tidsskr Nor Legeforen 2009; 129: 2252-5. Tidsskrift for Den norske legeforening
  52. Farber A, Menard MT, Conte MS, et al. Surgery or Endovascular Therapy for Chronic Limb-Threatening Ischemia. N Engl J Med 2022. pmid:36342173 PubMed
  53. Kurth T, Rist PM, Ridker PM, et al. Association of Migraine With Aura and Other Risk Factors With Incident Cardiovascular Disease in Women. JAMA 2020; 323: 2281-9. pmid:32515815 PubMed
  54. Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med. 2020. PMID: 32222135 PubMed
  55. US Preventive Services Task Force Recommendation Statement. Screening for Peripheral Artery Disease and Cardiovascular Disease Risk Assessment With the Ankle-Brachial Index. JAMA 2018; 320: 177-183. doi:10.1001/jama.2018.8357 DOI
  56. Robertson L, Ghouri MA, Kovacs F. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev 2012; 8: CD002071. The Cochrane Library
Annonse
Annonse